The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54 percent, according to a new study.
The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54 percent, according to a new study.